4/24
01:26 pm
pen
Penumbra's (PEN) New Launch to Enhance Blood Clot Removal [Yahoo! Finance]
Low
Report
Penumbra's (PEN) New Launch to Enhance Blood Clot Removal [Yahoo! Finance]
4/23
11:08 am
pen
Here's Why Penumbra (PEN) is a Strong Growth Stock [Yahoo! Finance]
Low
Report
Here's Why Penumbra (PEN) is a Strong Growth Stock [Yahoo! Finance]
4/23
09:10 am
pen
Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots [Yahoo! Finance]
Low
Report
Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots [Yahoo! Finance]
4/23
09:00 am
pen
Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots
Low
Report
Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots
4/9
04:05 pm
pen
Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024
Low
Report
Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024
4/8
11:45 am
pen
Here's Why You Should Retain Penumbra (PEN) Stock for Now [Yahoo! Finance]
Low
Report
Here's Why You Should Retain Penumbra (PEN) Stock for Now [Yahoo! Finance]
4/3
12:12 pm
pen
Penumbra, Inc. (NYSE: PEN) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $290.00 price target on the stock.
Low
Report
Penumbra, Inc. (NYSE: PEN) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $290.00 price target on the stock.
3/22
09:23 am
pen
Penumbra, Inc. (NYSE: PEN) had its price target lowered by analysts at Truist Financial Co. from $290.00 to $280.00. They now have a "buy" rating on the stock.
Low
Report
Penumbra, Inc. (NYSE: PEN) had its price target lowered by analysts at Truist Financial Co. from $290.00 to $280.00. They now have a "buy" rating on the stock.
3/5
11:11 am
pen
Penumbra (PEN) Gains From Innovation, Mounting Costs Ail [Yahoo! Finance]
Medium
Report
Penumbra (PEN) Gains From Innovation, Mounting Costs Ail [Yahoo! Finance]
2/28
05:27 am
pen
Intracranial Stents Market Projected to Achieve USD 3.4 billion by 2031, with a 5.2% CAGR Growth: Transparency Market Research, Inc. [Yahoo! Finance]
Medium
Report
Intracranial Stents Market Projected to Achieve USD 3.4 billion by 2031, with a 5.2% CAGR Growth: Transparency Market Research, Inc. [Yahoo! Finance]
2/27
11:22 am
pen
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term [Yahoo! Finance]
Low
Report
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term [Yahoo! Finance]
2/26
04:20 pm
pen
Penumbra Q4: Solid Is Not Good Enough [Seeking Alpha]
Low
Report
Penumbra Q4: Solid Is Not Good Enough [Seeking Alpha]
2/26
01:08 pm
pen
Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase [Yahoo! Finance]
Low
Report
Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase [Yahoo! Finance]
2/23
02:14 pm
pen
Penumbra, Inc. (NYSE: PEN) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $290.00 price target on the stock, down previously from $310.00.
Low
Report
Penumbra, Inc. (NYSE: PEN) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $290.00 price target on the stock, down previously from $310.00.
2/23
12:15 pm
pen
Penumbra, Inc. (NYSE: PEN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $289.00 price target on the stock.
Low
Report
Penumbra, Inc. (NYSE: PEN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $289.00 price target on the stock.
2/23
10:50 am
pen
Penumbra, Inc. (NYSE:PEN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Penumbra, Inc. (NYSE:PEN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/23
10:12 am
pen
Penumbra, Inc. (NYSE: PEN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $284.00 price target on the stock.
Low
Report
Penumbra, Inc. (NYSE: PEN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $284.00 price target on the stock.
2/23
09:00 am
pen
Penumbra, Inc. (NYSE: PEN) had its price target lowered by analysts at Truist Financial Co. from $300.00 to $290.00. They now have a "buy" rating on the stock.
Low
Report
Penumbra, Inc. (NYSE: PEN) had its price target lowered by analysts at Truist Financial Co. from $300.00 to $290.00. They now have a "buy" rating on the stock.
2/23
07:31 am
pen
Penumbra, Inc. (NYSE: PEN) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $250.00 price target on the stock, down previously from $284.00.
Low
Report
Penumbra, Inc. (NYSE: PEN) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $250.00 price target on the stock, down previously from $284.00.
2/23
12:25 am
pen
Decoding Penumbra Inc (PEN): A Strategic SWOT Insight [Yahoo! Finance]
Medium
Report
Decoding Penumbra Inc (PEN): A Strategic SWOT Insight [Yahoo! Finance]
2/22
04:50 pm
pen
Penumbra Inc (PEN) Reports Robust Revenue Growth and Profitability in Q4 and Full Year 2023 [Yahoo! Finance]
Low
Report
Penumbra Inc (PEN) Reports Robust Revenue Growth and Profitability in Q4 and Full Year 2023 [Yahoo! Finance]
2/22
04:05 pm
pen
Penumbra, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
Medium
Report
Penumbra, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
2/15
11:53 am
pen
Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release [Yahoo! Finance]
Low
Report
Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release [Yahoo! Finance]
2/7
04:29 am
pen
Neurovascular Devices Market Increase to USD 6.2 Billion by 2033 | Remarkable 7.6% CAGR [Yahoo! Finance]
Low
Report
Neurovascular Devices Market Increase to USD 6.2 Billion by 2033 | Remarkable 7.6% CAGR [Yahoo! Finance]
2/1
04:05 pm
pen
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 22, 2024
Low
Report
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 22, 2024